Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

raltegravir

- PMLiVE

A new option for people with HIV

ViiV Healthcare's dolutegravir could capture a significant share of the HIV market and may have blockbuster potential

- PMLiVE

Mylan to sell Gilead’s medicines in India

Includes HIV treatments Viread, Truvada and Stribild

- PMLiVE

ViiV wins European approval for Tivicay

HIV treatment licensed in combination with other anti-retroviral drugs

- PMLiVE

FDA panel backs Merck’s vorapaxar

On course for US approval to reduce vascular events in certain patients

- PMLiVE

Merck shares jump on melanoma drug filing

MK-3475 could be approved by end of 2014

- PMLiVE

FDA clears Isentress formulation for infants with HIV

Merck's integrase inhibitor available for children as young as four weeks

Biogen Idec building

Biogen Idec licenses anti-TNF biosimilars

Treatment prospects emerge from joint venture with Samsung Biologics

- PMLiVE

Merck takes Alzheimer’s hope into phase III

MK-8931 moves to late-stage study after positive early data

- PMLiVE

Technology-enhanced HIV testing service triumphs

Dean Street at Home initiative wins PMEA's digital/social award

- PMLiVE

ViiV’s Tivicay for HIV on course for EU approval

More positive news for GSK, Pfizer and Shionogi joint venture

- PMLiVE

Merck’s melanoma drug shows survival benefit

MK-3475 shows promise in phase Ib

- PMLiVE

J&J files HIV combination in Europe

Seeks approval for fixed-dose tablet containing Prezista and Gilead’s cobicistat

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links